ImmunityBio (NASDAQ:IBRX) Stock Price Crosses Below 200-Day Moving Average on Disappointing Earnings

Key Points

• ImmunityBio shares fell below their 200-day moving average, trading as low as $6.36 after the earnings announcement.
• The company reported a quarterly loss of $0.09 per share, versus the $0.07 loss analysts expected, and revenue of $48.84 million, below the $59.23 million consensus.
• Despite year-over-year product revenue growth and positive ANKTIVA trial and regulatory news, ImmunityBio raised substantial doubt about its ability to continue without additional funding.

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday following a weaker than expected earnings announcement. The stock has a 200-day moving average of $7.96 and traded as low as $6.36. ImmunityBio shares last traded at $7.11, with a volume of 44,782,144 shares trading hands.

The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). The business had revenue of $48.84 million for the quarter, compared to the consensus estimate of $59.23 million.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Third-quarter net product revenue rose 53% year over year to $48.7 million, while U.S. revenue for the first nine months increased 92% to $143.6 million. ImmunityBio Q3 2026 results and approvals
• Positive Sentiment: ANKTIVA plus BCG met the primary endpoint in a randomized trial for BCG-naïve, high-grade non-muscle-invasive bladder cancer, a potential clinical and commercial catalyst. QUILT-2.005 trial results
• Positive Sentiment: The company also reported an expanded FDA label and an additional global approval for ANKTIVA, broadening its regulatory reach. ImmunityBio Q3 2026 results and approvals
• Neutral Sentiment: Trading in IBRX call options was unusually active, with volume 86% above its typical level; this does not establish a clear direction for the stock.
• Negative Sentiment: ImmunityBio reported a quarterly loss of $0.09 per share, worse than the $0.07 consensus estimate. Revenue of about $48.8 million also missed analysts’ $59.2 million forecast, and product sales declined from the prior quarter despite year-over-year growth. Q3 loss and revenue miss
• Negative Sentiment: The company disclosed “substantial doubt” about its ability to continue without additional funding, raising concerns about potential financing or dilution. The earnings miss and funding risk appear to be overshadowing the growth and pipeline news. Earnings, valuation, and funding concerns

Wall Street Analysts Forecast Growth

IBRX has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of ImmunityBio in a research note on Thursday, October 15th. Jefferies Financial Group boosted their target price on ImmunityBio from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday, October 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ImmunityBio in a research note on Tuesday, October 6th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $16.00 price target on shares of ImmunityBio in a report on Wednesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

Insiders Place Their Bets

In other news, Director Barry Simon sold 25,000 shares of the firm's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the transaction, the director directly owned 2,777,788 shares in the company, valued at $29,861,221. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the company's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the sale, the director owned 100,309 shares of the company's stock, valued at $1,053,244.50. This represents a 44.69% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 66.10% of the company's stock.

Institutional Trading of ImmunityBio

A number of institutional investors and hedge funds have recently modified their holdings of IBRX. Sigma Planning Corp increased its stake in ImmunityBio by 7.3% in the second quarter. Sigma Planning Corp now owns 19,015 shares of the company's stock valued at $166,000 after purchasing an additional 1,300 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of ImmunityBio by 2.0% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 76,000 shares of the company's stock worth $717,000 after purchasing an additional 1,500 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in shares of ImmunityBio by 1.5% during the third quarter. Commonwealth Equity Services LLC now owns 145,829 shares of the company's stock worth $1,377,000 after purchasing an additional 2,113 shares in the last quarter. Archer Investment Corp boosted its position in shares of ImmunityBio by 67.1% during the first quarter. Archer Investment Corp now owns 5,872 shares of the company's stock worth $45,000 after purchasing an additional 2,358 shares in the last quarter. Finally, Profund Advisors LLC grew its holdings in shares of ImmunityBio by 1.4% in the 3rd quarter. Profund Advisors LLC now owns 179,021 shares of the company's stock valued at $1,690,000 after buying an additional 2,518 shares during the period. 8.58% of the stock is owned by institutional investors.

ImmunityBio Trading Down 17.7%

The company has a market cap of $7.54 billion, a price-to-earnings ratio of -7.33 and a beta of 0.17. The firm's fifty day moving average price is $8.72 and its 200-day moving average price is $7.96.

ImmunityBio Company Profile

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body's natural and adaptive immune responses.

The company's lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.